Danaher (NYSE:DHR – Get Free Report) released its quarterly earnings results on Tuesday. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15, Briefing.com reports. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 10.90%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.05 earnings per share.
Danaher Trading Up 0.6 %
Shares of DHR opened at $265.76 on Thursday. The firm has a fifty day simple moving average of $254.89 and a two-hundred day simple moving average of $248.67. Danaher has a twelve month low of $182.09 and a twelve month high of $272.98. The stock has a market capitalization of $196.85 billion, a P/E ratio of 45.04, a PEG ratio of 4.11 and a beta of 0.83. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.
Danaher Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.41%. Danaher’s dividend payout ratio is currently 18.31%.
Analysts Set New Price Targets
Insider Activity
In related news, CEO Rainer Blair sold 19,085 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $29,578,725. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Rainer Blair sold 19,085 shares of Danaher stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,175 shares of company stock valued at $19,161,154. Insiders own 11.10% of the company’s stock.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- How Technical Indicators Can Help You Find Oversold Stocks
- How Much Should You Be Investing? Try Our Calculators
- How to Invest in Biotech Stocks
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.